

7 July 2009

## Proposal to list fluticasone nasal spray (Flixonase) in the Pharmaceutical Schedule

PHARMAC is seeking feedback on a proposal to list the Flixonase brand of fluticasone nasal spray in the Pharmaceutical Schedule from 1 January 2010.

### Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5 pm on **Tuesday, 21 July 2009** to:

Sean Dougherty  
Therapeutic Group Manager  
PHARMAC  
PO Box 10 254  
Wellington 6143

Email: [sean.dougherty@pharmac.govt.nz](mailto:sean.dougherty@pharmac.govt.nz)

Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

### Details of the proposal

Flixonase would be listed in Section B of the Pharmaceutical Schedule from 1 January 2010 at the following price and subsidy (ex-manufacturer, exclusive of GST):

Chemical	Presentation	Brand	Pack size	Price and subsidy
Fluticasone propionate	Metered aqueous nasal spray, 50 µg per dose	Flixonase	120 dose OP	\$3.38

Flixonase would be the sole subsidised supply brand of fluticasone nasal spray, and would be protected from subsidy and delisting protection, until 31 December 2012.

### Background

Fluticasone nasal spray is used for the short-term treatment and prevention of seasonal allergic rhinitis, including hayfever. Fluticasone nasal spray is not currently listed in the Pharmaceutical Schedule, however other intra-nasal corticosteroids, beclomethasone and budesonide, are currently (and would remain) funded.

We initiated a competitive process for supply of fluticasone nasal spray. Subsequent to this, we have entered into a provisional agreement with GlaxoSmithKline Consumer Healthcare for Flixonase to be listed as the sole subsidised supply brand of fluticasone nasal spray.